Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species.
For infections with antibiotic-susceptible strains of Pseudomonas aeruginosa, most studies have suggested that combination therapy, usually with a beta -lactam antibiotic plus an aminoglycoside, is preferable for patients with bacteremia and neutropenia. Against infections with Pseudomonas aeruginosa or Acinetobacter baumannii isolates that are resistant to all antibiotics except the polymyxins, several novel antibiotic combinations demonstrate increased activity in vitro compared with that of any single agent. Whether these combinations yield outcomes that are improved over those seen with a polymyxin or other agent alone remains to be determined. However, against infections with species resistant to all antibiotics, including polymyxins, novel combinations are the only remaining therapeutic option.
Rahal
James J
JJ
Infectious Disease Section and Lang Research Center, New York Hospital Queens, and Department of Medicine, Weill College of Medicine, Cornell University, New York, New York 11355-5095, USA. jjr9002@nyp.org
D000150:Acinetobacter / Q000187:drug effects; D000151:Acinetobacter Infections / Q000188:drug therapy*; D000617:Aminoglycosides / Q000008:administration & dosage; D002986:Clinical Trials as Topic / Q000379:methods; D024901:Drug Resistance, Multiple, Bacterial; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D011113:Polymyxins / Q000008:administration & dosage; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D015363:Quinolones / Q000008:administration & dosage; D047090:beta-Lactams / Q000008:administration & dosage
D000617:Aminoglycosides; D011113:Polymyxins; D015363:Quinolones; D047090:beta-Lactams